Bio-Gene Technology (ASX:BGT) Scaled Net Operating Assets: 0.04 (As of Dec. 2025)


What is Bio-Gene Technology Scaled Net Operating Assets?

Bio-Gene Technology ASX:BGT -15.00% Scaled Net Operating Assets is 0.04 as of Dec. 2025. The stock has 2 warning signs investors should review.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Bio-Gene Technology's operating assets for the quarter that ended in Dec. 2025 was A$0.39 Mil. Bio-Gene Technology's operating liabilities for the quarter that ended in Dec. 2025 was A$0.31 Mil. Bio-Gene Technology's Total Assets for the quarter that ended in Jun. 2025 was A$2.15 Mil. Therefore, Bio-Gene Technology's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2025 was 0.04.

Bio-Gene Technology Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Bio-Gene Technology's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio-Gene Technology Scaled Net Operating Assets Chart

Bio-Gene Technology Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Scaled Net Operating Assets
Get a 7-Day Free Trial 0.05 -0.02 0.03 0.15 0.16

Bio-Gene Technology Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.12 0.14 0.05 0.26 0.04

ASX:BGT vs VRTX, REGN, ALNY: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, Bio-Gene Technology's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bio-Gene Technology Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bio-Gene Technology's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Bio-Gene Technology's Scaled Net Operating Assets falls into.


Bio-Gene Technology Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Bio-Gene Technology's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Jun. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(A: Jun. 2025 )
=(Operating Assets (A: Jun. 2025 )-Operating Liabilities (A: Jun. 2025 ))/Total Assets (A: Jun. 2024 )
=(1.012-0.523)/3.16
=0.15

where

Operating Assets(A: Jun. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=2.15 - 1.138
=1.012

Operating Liabilities(A: Jun. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=0.523 - 0 - 0
=0.523

Bio-Gene Technology's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Dec. 2025 )
=(Operating Assets (Q: Dec. 2025 )-Operating Liabilities (Q: Dec. 2025 ))/Total Assets (Q: Jun. 2025 )
=(0.393-0.308)/2.15
=0.04

where

Operating Assets(Q: Dec. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=1.474 - 1.081
=0.393

Operating Liabilities(Q: Dec. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=0.308 - 0 - 0
=0.308

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of 0.04 mean?
Bio-Gene Technology (ASX:BGT) has a Scaled Net Operating Assets of 0.04 as of Dec. 2025. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Bio-Gene Technology and its competitors.
Is Bio-Gene Technology's Scaled Net Operating Assets too high?
Bio-Gene Technology's current Scaled Net Operating Assets is 0.04.
How does Bio-Gene Technology's Scaled Net Operating Assets compare to VRTX and REGN?
Bio-Gene Technology's Scaled Net Operating Assets of 0.04 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Bio-Gene Technology and its competitors. Bio-Gene Technology's current Scaled Net Operating Assets is 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Gene Technology stock overvalued right now?
Bio-Gene Technology (ASX:BGT) has a current Scaled Net Operating Assets of 0.04. The current Scaled Net Operating Assets is 0.04. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Bio-Gene Technology (ASX:BGT), the current Scaled Net Operating Assets is 0.04 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bio-Gene Technology Business Description

Address 400 Collins Street, Level 6, Melbourne, VIC, AUS, 3000
Bio-Gene Technology Ltd is an Australian company developing novel bio-insecticides to address the challenges of insecticide resistance and toxicity. Its products are based on a naturally occurring class of compounds to overcome resistance to control pests with minimal impact on human health and the environment. Bio-Gene's products have multiple applications across public health, crop protection, grain storage, and consumer use. The company operates in one business segment, being the conduct of research and development activities in the discovery of novel insecticides.